We aimed to prospectively assess limb volume change (LVC) and associated symptoms in patients with melanoma undergoing sentinel lymph node biopsy and/or therapeutic lymph node dissection. Limb volume was measured preoperatively and postoperatively at 6 and 12 months using a perometer (1000 mol/l). LVC was calculated and used to define three groups: less than 5%, 5-10%, and greater than 10%. A 19-item lymphedema symptom questionnaire was administered at baseline, 6, and 12 months. One hundred and eighty-two patients were enrolled. Twelve months after axillary surgery, 9% had LVC 5-10% and 13% had LVC greater than 10%. Twelve months after inguinofemoral surgery, 10% had LVC 5-10% and 13% had LVC greater than 10%. There was a significant sevento nine-fold increase in symptoms for patients with LVC greater than 10% compared with those with LVC less than 5% (P < 0.05). On multivariate analysis, therapeutic lymph node dissection versus sentinel lymph node biopsy (odds ratio = 3.18; P < 0.01) and borderline significance for lower-extremity versus upper-extremity procedures (odds ratio = 1.72; P = 0.07) were associated with LVC greater than 5%. LVC greater than 5% is common at 12 months following nodal surgery for melanoma and is associated with symptoms. Informed consent for melanoma patients undergoing lymph node surgery should include a discussion of the risks of postoperative lymphedema.
We aimed to prospectively assess limb volume change (LVC) and associated symptoms in patients with melanoma undergoing sentinel lymph node biopsy and/or therapeutic lymph node dissection. Limb volume was measured preoperatively and postoperatively at 6 and 12 months using a perometer (1000 mol/l). LVC was calculated and used to define three groups: less than 5%, 5-10%, and greater than 10%. A 19-item lymphedema symptom questionnaire was administered at baseline, 6, and 12 months. One hundred and eighty-two patients were enrolled. Twelve months after axillary surgery, 9% had LVC 5-10% and 13% had LVC greater than 10%. Twelve months after inguinofemoral surgery, 10% had LVC 5-10% and 13% had LVC greater than 10%. There was a significant sevento nine-fold increase in symptoms for patients with LVC greater than 10% compared with those with LVC less than 5% (P < 0.05). On multivariate analysis, therapeutic lymph node dissection versus sentinel lymph node biopsy (odds ratio = 3.18; P < 0.01) and borderline significance for lower-extremity versus upper-extremity procedures (odds ratio = 1.72; P = 0.07) were associated with LVC greater than 5%. LVC greater than 5% is common at 12 months following nodal surgery for melanoma and is associated with symptoms. 
Introduction
Secondary lymphedema is a complication affecting many patients after surgical resection of primary or regionally metastatic solid tumors, including melanoma [1] . The clinical impact of lymphedema has been difficult to assess accurately patients with melanoma of variance in definition and reported incidence [1] . All published studies to date on lymphedema after surgery for melanoma have been retrospective [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and many of those studies have used subjective criteria to define lymphedema [4, 5] . Because of the lack of prospective assessment with objective measurement tools and the lack of consensus on the definition of lymphedema, there remains little understanding of the true incidence of lymphedema in patients who have undergone surgery for melanoma. A delay in the diagnosis of lymphedema prevents early treatment of this progressive, morbid condition, and the cascade of associated physical and psychosocial impairments can disrupt recovery and cancer-directed therapies, as has been described in the breast cancer literature [15] . The clinical impact of varying degrees of change in limb volume has only recently been addressed in patients with breast cancer [16] and the relationship between the degree of volume change and symptoms in patients with melanoma has not been reported.
The most frequently utilized objective measurement method for assessing lymphedema remains serial limb circumference measurement [3, [6] [7] [8] 11, 17] . The limitations of this method are primarily related to the specific anatomic locations measured and the total number of interval measures, as well as interobserver variability [2, 3, 10, 12] . More recently, an objective measurement method for assessing lymphedema using a perometer, an optoelectronic device that uses infrared light to calculate limb volume, has been applied in clinical and research settings, with promising results [16] .
The objective of our study was to estimate the incidence of postoperative lymphedema and associated symptoms in patients with stage I to III melanoma at 6 and 12 months after sentinel lymph node (SLN) biopsy and/or therapeutic lymph node dissection (TLND). We assessed limb volume using objective perometry and assessed symptoms using a validated 19-item instrument. We hypothesized that a number of patient-specific and treatment-specific risk factors would be associated with an increased risk of lymphedema, including elevated BMI, lower-extremity (vs. upper-extremity) procedure, extensive tumor nodal burden, and receipt of radiation therapy. We also hypothesized that even patients undergoing SLN biopsy alone would experience lymphedema and associated symptoms, as has been described in the breast cancer literature [18] .
Materials and methods

Patients
Patients were eligible for this prospective, longitudinal study if they had a confirmed diagnosis of invasive cutaneous melanoma, stage I to III, without a previous operation on the regional nodal basin at the time of enrollment. To participate in the study, patients were required to be fluent in English, be at least 18 years old, and provide informed consent. Patients with distant metastatic disease, implanted medical devices, or a concurrent malignancy that required active treatment before enrollment in the study were not eligible. Patients with a history of extremity trauma or surgery requiring insertion of screws or other metal joints were not eligible. All patients were evaluated and followed at The University of Texas MD Anderson Cancer Center. Baseline demographic and clinical data were obtained from each patient at the time of the initial interview. All patients enrolled in the study subsequently underwent SLN biopsy and/or TLND on the basis of standard clinical protocols. Patients returned for follow-up measurements and questionnaire completion at 3-6 months and 9-12 months. Study participants were instructed to avoid alcohol and exercise 24 h before measurement. Patient identification information was coded to ensure confidentiality. This study was approved by the Institutional Review Board.
Limb volume assessment
Limb volume was measured using an onsite Pero-System 1000 M perometer (Juzo, Cuyahoga Falls, Ohio, USA), an optoelectronic volumetry device that uses infrared light to calculate limb volume [19] , in a single designated clinic room with regulated temperature (711F) and humidity between the daylight hours of 9 a.m. and 4 p.m. For each patient, limb volume was measured preoperatively (baseline) and then at 6 and 12 months postoperatively; both the limb on the affected side and the contralateral limb were measured while in the standing position. Upper-extremity measurements were performed at a 451 angle while holding a fixed marker and guiding the perometer from the styloid process of the ulna to the limiting point of the axilla. Lower-extremity measurements were performed while standing upright; the frame of the perometer was guided from the lateral malleolus to the limiting point of the perineum.
At the time of limb volume assessment, patients with signs and symptoms of limb swelling and patients with a greater than 10% adjusted increase in the volume of the affected limb from baseline (according to the formula below) were referred for a consultation with a lymphedema healthcare provider while continuing clinical follow-up. Limb volume change (LVC) on the affected side between baseline and follow-up was expressed as a percentage of the baseline limb volume and calculated according to the following formula [18] :
where I indicates the volume of the ipsilateral (affected) limb and C indicates the volume of the contralateral limb. The change in volume of the contralateral limb was subtracted from the change in volume of the affected limb to account for changes in patient body weight between assessments and then divided by I baseline and multiplied by 100%. The adjustment for changes in weight over time on the basis of differences between the ipsilateral (affected) and the contralateral limb is likely underestimated in patients undergoing bilateral procedures. Three LVC groups were defined: less than 5% (no or latent lymphedema [20] ), 5-10% (at-risk to develop lymphedema), and greater than 10% (lymphedema) [21] . Although arbitrary, these LVC categories have been shown to be associated with symptom assessment changes in previous longitudinal studies in patients with breast cancer [16] . Identification of the at-risk group targets subsets of patients who may benefit from proposed prospective lymphedema surveillance models and rehabilitation, such as those utilized in patients with breast cancer [22] .
Symptom assessment
To assess for lymphedema-associated symptoms, we used a previously validated questionnaire, the Lymphedema and Breast Cancer Questionnaire [23] , which has been modified to include assessment of lower-extremity symptoms. The questionnaire inquires about symptoms including tenderness, swelling, redness, blistering, numbness, stiffness, and tightness, among others. Patients completed the 19-item symptom assessment tool at the preoperative (baseline) visit and 6 and 12 months later. Scores reported reflect the number of affirmative responses. For each patient and for each follow-up assessment (6 and 12 months), the change in the symptom score between baseline and follow-up was calculated by subtracting the total number of affirmative responses at baseline from the total number of affirmative responses at follow-up. The effect of LVC on symptom score was investigated using a nonparametric analysis of variance test (Kruskal-Wallis) with a P-value for significance of 0.05.
Statistical analysis
A mixed longitudinal logistic regression model was used to examine whether the variables age, BMI (kg/m 2 ), upper-extremity versus lower-extremity surgery, and SLN biopsy versus TLND were associated with the magnitude of LVC for patients with LVC of at least 5%. Covariates adjusted in the regression model were based on their significance in univariate analyses. Although tumor burden and radiation therapy were included in univariate analysis, they were not found to be statistically significant with LVC greater than 5% and therefore were not included in the multivariate model. All the reported P-values were two sided and values less than 0.05 were considered statistically significant. The statistical analyses were carried out using SAS software, version 9.2 (SAS Inc., Cary, North Carolina, USA).
Results
Patient characteristics and treatment details
A total of 182 patients had enrolled in the study at the time of this analysis. The characteristics of the patients at baseline are summarized in Table 1 . There were slightly more men (52.7%) than women (47.3%), and the majority of the patients (61.5%) were older than 50 years of age. The median weight for the cohort was 85.3 kg, and 75% of the patients were either overweight (38% with BMI Z 25) or obese (37.4% with BMI Z 30). A total of 46.2% of the patients underwent SLN biopsy alone and 53.8% of the patients underwent TLND with or without a prior SLN biopsy. Most patients (78%), irrespective of the procedure, had either microscopic or no lymph node disease. Of the 98 patients undergoing TLND, 44 (44.9%) had an axillary dissection, whereas 29 (29.6%) had a superficial inguinofemoral node dissection alone and 25 (25.5%) underwent a deep iliac/obturator node dissection in addition to a superficial node dissection. The majority of the patients (62.6%) were diagnosed with a primary melanoma of the extremity. Only 11% of the patients received radiation therapy as part of their therapy.
Limb volume change
Follow-up information was available for 154 patients at 6 months and 117 patients at 12 months (Table 1) . At both 6 and 12 months, obese patients had a higher incidence of LVC greater than 10% than did patients with lower BMI. Similarly, at both 6 and 12 months, patients with melanomas of the lower extremity had a higher incidence of LVC greater than 10% than did patients with melanomas of the upper extremity and patients who underwent TLND had a higher incidence of LVC greater than 10% than did patients who underwent SLN biopsy alone. For patients who underwent TLND, there were a higher percentage of patients who had a combined superficial and deep iliac/obturator dissection who fulfilled the criteria for at-risk and lymphedema at 12 months compared with the superficial inguinofemoral node dissection alone. In patients who underwent SLN biopsy alone, 15.8% fulfilled the criteria for at-risk (LVC 5-10%) and 13.2% fulfilled the criteria for lymphedema (LVC > 10%) at the 6-month follow-up assessment; at the 12-month assessment, 14.8% fulfilled the criteria for at-risk and 14.8% for lymphedema. Radiation therapy was associated with an increased risk of LVC greater than 10% compared with no radiation therapy at 12 months but not at 6 months.
Symptoms and correlation with limb volume change
The most commonly reported symptoms at the 6-month follow-up assessment were numbness (42%), firmness/ tightness (37%), swelling (31%), and tenderness (25%). At 12 months, the most commonly reported symptoms were similar: numbness (32.4%), swelling (29.8%), firmness/tightness (25.8%), and tenderness (13.5%). At baseline, the mean symptom score for all patients was 1.3 [95% confidence interval (CI): 0.9; 1.7]. At both the 6-and 12-month follow-ups, patients with LVC of greater than 10% experienced more lymphedema-associated symptoms than patients with LVC less than 5% (P = 0.001). Patients with LVC greater than 10% experienced the greatest number of symptoms at 12 months (P = 0.001) ( Fig. 1a ). At 12 months, patients with LVC of greater than 5% but less than 10% showed a significant increase in the mean reported symptom scores (P = 0.046). When stratified by upper versus lower extremity, lower-extremity patients had a statistically significant greater overall mean symptom score compared with upper-extremity patients at 12 months (P = 0.01) ( Fig. 1b) . At 6 months, statistically significant differences were found in both upper and lower-extremity TLND compared with patients undergoing SLN biopsy of the upper extremity (P = 0.002 and 0.003, respectively) and by the 12-month evaluation lower-extremity TLND patients reported a statistically significant difference in symptoms compared with upper-extremity SLN biopsy patients (P = 0.046, Fig. 2 ). Irrespective of the site of operation, the mean change in symptom score at both 6 and 12 months was higher in patients with greater LVC ( Table 2 ). The mean symptom score was highest for patients who underwent TLND than for patients who underwent SLN biopsy for both lower-extremity and upper-extremity operations (Fig. 2) .
Patients with a primary melanoma on the extremity and patients with a primary melanoma on the trunk showed similar changes in symptom score at both 6 and 12 months ( Table 2 ). Clinically evident nodal disease was associated with higher median change in symptom score than microscopic nodal disease at 12 months (Table 2) .
Multivariate regression analysis
On univariate analysis, risk factors associated with LVC greater than 5% included older age (> 50 years), obesity (BMI > 30), lower-extremity (vs. upper-extremity) procedure, and TLND (vs. SLN biopsy). On multivariate regression analysis, TLND (vs. SLN biopsy) was significantly associated with LVC greater than 5% (odds ratio = 3.18; 95% CI: 1.75-5.78; P < 0.01) ( Table 3) . Lower-extremity procedures were also associated with an increased risk for LVC greater than 5% compared with upper-extremity procedures, but this difference was not statistically significant (odds ratio = 1.72; 95% CI: 0.96-3.07; P < 0.07).
Discussion
In this study, we prospectively and objectively assessed lymphedema and associated symptoms at 6 and 12 months after lymph node surgery in a series of patients with stage I to III melanoma. Overall, at 12 months, we found that lymphedema (LVC > 10%) was common in patients who underwent SLN biopsy only (14.8%), as well as in patients who underwent TLND (30.4%). Our hypothesis that patient-specific and treatment-specific factors would be associated with higher incidences of LVC was confirmed; multivariate regression analysis identified TLND (vs. SLN biopsy) and lower-extremity procedures (vs. upper extremity) as independent risk factors associated with an increased risk of LVC greater than 5% (Table 3) . With respect to lymphedemaassociated symptoms, we found that lower-extremity procedures were associated with increases in patientreported symptoms, irrespective of whether SLN biopsy only or TLND was performed and irrespective of the magnitude of LVC ( Table 2 , Fig. 1b ). The mean symptom scores increased significantly in all patient subgroups examined as early as 6 months (Fig. 1a ). Together, these data confirm our additional hypothesis that lymphedema can occur and its associated symptoms can be clinically significant in patients undergoing SLN biopsy alone.
Definitions of lymphedema vary within the literature, but generally, the threshold for a diagnosis of lymphedema is a greater than 10-20% change in limb volume for water displacement studies or a girth increase of greater than 2 cm at any location on a limb using circumference measurements. For this study, lymphedema was defined as LVC greater than 10% but we also stratified patients by LVC of 5-10% because this threshold for at-risk patients has also been identified as clinically relevant for patients with breast cancer in contemporary studies [16] .
Among patients who underwent TLND at 12 months, the incidence of lymphedema was higher among patients who underwent lower-extremity procedures than among those who underwent upper-extremity procedures (27.1 vs. 18.8%). Previous studies using objective measures have reported that the incidence of lymphedema in melanoma patients ranges between 7 and 17% when water displacement methods are used [3, 24] and between 1 and 12.5% when circumference measurements are used [6] [7] [8] 25] . Our findings are consistent with the literature in that lower-extremity procedures (particularly inguinofemoral dissection) have been reported to be associated with higher incidences of lymphedema than upper-extremity procedures; reported incidences of lymphedema for lower-extremity procedures are 18-58% using water displacement methods [2,10,12] and 14-61% using circumference measurement [6-9,11,13,17,25]. Mean of total symptoms score 
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Mean symptom assessment scores at 6 months (T1) and 12 months (T2) stratified by limb volume change expressed as a percentage of the limb volume at baseline (a) and by site of lymph node surgery (b).
A novel aspect of this report is the inclusion and characterization of patients treated only with SLN biopsy. We found that 14.8% of patients treated with SLN biopsy only had lymphedema at 6 months and 14.8% had lymphedema at 12 months (Table 1 ). When we stratified the patients who underwent SLN biopsy only by the anatomic location of surgery, we found that at 12 months, the percentages of patients fulfilling the criteria of at-risk and lymphedema were 13.0 and 18.4%, respectively, among patients who underwent upper-extremity surgery, and 20.8 and 27.1%, respectively, among patients who underwent lower-extremity SLN surgery (Table 1) . These rates appear to be higher than other reported rates of lymphedema following SLN biopsy, which are from retrospective studies: mild lymphedema (10-20% water displacement) in 11.3% of patients undergoing upper-extremity surgery and 6% of patients undergoing lower-extremity surgery with unspecified followup [2, 24] . However, our findings on the incidence of lymphedema following upper-extremity SLN biopsy are consistent with the 1-17% reported incidence of lymphedema in patients undergoing SLN biopsy for breast cancer [26, 27] .
Our study makes novel contributions toward the melanoma literature. Using infrared perometry, we could objectively quantify the change in limb volume over time in a prospective manner. To our knowledge, this is the first published report of objective measurement of lymphedema in patients with melanoma undergoing SLN biopsy. In addition, we examined the relationships between the degree of LVC and lymphedema-associated symptoms ( Table 2 ). We found that in most of the LVC subgroups, symptom scores at both 6 and 12 months were significantly higher than in patients with no LVC. When we compared our findings with findings from a similar prospective analysis of lymphedema in breast cancer patients undergoing axillary procedures [16] , we found similar increases in lymphedema-associated symptom scores corresponding with increasing severity of LVC ( Table 2 , Fig. 1 ). Furthermore, we found that the most commonly reported increased symptoms (numbness, firmness/tightness, swelling, and tenderness) were similar between melanoma and breast cancer patients. Within the melanoma literature, lymphedema-associated symptoms have been variably defined and inconsistently reported; however, the symptoms described in our study largely overlap with the commonly described symptoms of dysesthesia, perception of swelling, pain, fatigue, and functional limitation [2, 3, 24, 25, 28] . This study also noted that a small subset of patients reported symptoms without significant LVC. The reasons for this may be attributed to ongoing symptoms associated with their surgery (e.g. tenderness, numbness, and aching) as well as swelling of the truncal regions (e.g. breast or perineum), which cannot be measured objectively.
Our study also has some limitations. The first is the relatively small number of patients, which limits analyses of several subsets, especially at the 12-month follow-up for lower-extremity procedures. As the cohort matures, additional data will be available for the final 30-month analysis of LVC. In addition, the relatively small number of patients who underwent radiation therapy (n = 20) did not allow for an accurate assessment of the effects of radiation therapy on the development of lymphedema among melanoma patients. Furthermore, the authors did not stratify patients according to tumor 1 versus 2 cm wide local excision of the primary tumor site, but did adjust for anatomic site of the primary tumor in the final analysis; only five patients required skin grafts in this study without an impact on LVC, which is in contrast to a previous study that showed an influence on the incidence of lymphedema [29] . Furthermore, the protocol did not collect precise data on weather conditions on the day of measurement, which, in a study of 171 breast cancer patients with chronic lymphedema, have been shown to be predictive of response to complete decongestive therapy and may also impact precise measurements [30] . Caution should be exercised in generalizing conclusions on the basis of 12 months of follow-up, as the breast cancer literature reports new diagnoses of lymphedema up to and even beyond 24 months after surgery [31, 32] .
Conclusion
We believe that our methods and findings provide a blueprint for future prospective studies evaluating postoperative lymphedema in cancer patients. Early detection of lymphedema with early referral for intervention has been shown to halt progression and alleviate symptoms and associated complications of lymphedema [33] . Measurement tools for LVC such as the perometer remain cost prohibitive for widespread implementation to clinical practice; however, there are less expensive techniques such as circumference measurements with protocols that designate specific anatomic locations that also report high inter-rater reliability but can be time consuming in a patient care setting [34, 35] . Early intervention with compression and physical therapy has been reported to improve the quality of life of breast cancer patients with LVC as low as 3% LVC [33] . The detection of measurable lymphedema and associated symptoms in melanoma patients who have undergone SLN biopsy and/or TLND mandates discussion of the risks of developing clinically significant lymphedema with its commonly reported symptoms such as numbness, firmness/tightness, swelling, and tenderness. These issues should be raised as an essential part of the informed consent process for patients with melanoma for whom surgery is recommended. This ongoing study will continue to accrue patients to further clarify the risk of lymphedema and associated symptoms for this at-risk population.
